N-Acetyl Semax

N-Acetyl Semax is an acetylated variant of Semax with enhanced stability, improved blood-brain barrier penetration, and potentially stronger nootropic effects. The acetyl modification protects against enzymatic degradation and may increase potency compared to standard Semax. Like its parent compound derived from ACTH (4-10), N-Acetyl Semax increases brain-derived neurotrophic factor (BDNF) expression, enhances dopamine and serotonin neurotransmission, and provides neuroprotective effects. Research suggests the acetylated form may produce more pronounced cognitive enhancement, including improved memory, attention, and mental clarity. The peptide demonstrates antioxidant properties and may protect against hypoxic and ischemic brain injury. N-Acetyl Semax is administered intranasally for direct brain delivery. Studies indicate potential applications for cognitive enhancement, depression, anxiety, stroke recovery, and neurodegenerative conditions. The modification allows for potentially lower dosing while maintaining or enhancing efficacy. Clinical use is primarily documented in Russian medical literature.

Peer-reviewed human evidence is dominated by older Russian studies of Semax itself; the N-acetyl variant lacks independent large trials, is not FDA-approved, and much circulating dosing/safety guidance is anecdotal or vendor-sourced.

Heptapeptide derived from ACTH(4-10) with N-terminal acetylation intended to improve enzymatic stability and blood-brain barrier penetration; administered intranasally; reported to raise BDNF and modulate dopaminergic/serotonergic transmission. Research/limited-regional-medicine status.